Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02526368 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
A Early Phase 1 study of Prostate Cancer and Localized Prostate Carcinoma, sponsored by Ivan de Kouchkovsky, MD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT02526368: Recruiting Early Phase 1 study of Prostate Cancer and Localized Prostate Carcinoma, sponsored by Ivan de Kouchkovsky, MD.
NCT02526368 is a Early Phase 1 study of Prostate Cancer and Localized Prostate Carcinoma that is actively recruiting participants, run by Ivan de Kouchkovsky, MD. The registered enrollment target is 80 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02526368, a Early Phase 1 study of Prostate Cancer and Localized Prostate Carcinoma, is actively recruiting participants, sponsored by Ivan de Kouchkovsky, MD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea works in finding prostate cancer that exhibits poorly differentiated or undifferentiated cells (high-grade) and that is restricted to the site of origin, without evidence of spread (localized) in patients undergoing radical prostatectomy. Diagnostic procedures, such as MRSI with hyperpolarized carbon (13C) pyruvate, may aid in the diagnosis of prostate cancer and in discriminating high-grade from low-grade prostate cancer and benign adjacent prostate tissue
Primary Outcome
Means and standard deviations for lactate area under curve will be calculated by pathologic grade (benign, low grade (primary Gleason score \<4) and high grade (primary Gleason score \>4)).
Conditions Studied
Interventions
- DRUG Hyperpolarized 13C-Pyruvate
- PROCEDURE Magnetic Resonance Spectroscopic Imaging
- DRUG Hyperpolarized 13C,15N2-urea
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-03-22 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
What NCT02526368 shows while recruiting
NCT02526368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Hyperpolarized 13C-Pyruvate is the first listed.
NCT02526368 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02526368 about?
NCT02526368 is a clinical study titled "Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer". This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea works in finding prostate cancer that exhibits poorly differentiated or undifferentiated cells (high-grade) and that is r...
What is the current status of trial NCT02526368?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2016-03-22. Estimated completion is 2026-12-31.
What conditions does trial NCT02526368 study?
This clinical trial studies the following conditions: Prostate Cancer, Localized Prostate Carcinoma.
What interventions are being tested in trial NCT02526368?
The interventions under investigation include: Hyperpolarized 13C-Pyruvate (DRUG), Magnetic Resonance Spectroscopic Imaging (PROCEDURE), Hyperpolarized 13C,15N2-urea (DRUG).
Who is sponsoring clinical trial NCT02526368?
This trial is sponsored by Ivan de Kouchkovsky, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02526368 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02526368's enrollment target sits among peer trials
80 370th of 735 higher than 355 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
RECRUITING · Early Phase 1
-
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
RECRUITING · Early Phase 1
-
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
RECRUITING · Early Phase 1
-
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
RECRUITING · Early Phase 1
-
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI